On Nov. 12, the Center for Medicare and Medicaid Services (CMS) announced the Medicare Part B (doctor’s care) premium rates for 2022 would rise from $148.50 per month in 2021, to $170.10 in 2022.
Archive | Pushback
Medicare Proposal Would Cover Aduhelm If Beneficiaries Enrolled In Clinical Trials
Posted on 17 January 2022.
Posted in Pushback0 Comments
Drug Companies Keep Prices High At The Expense Of Older Americans
Posted on 20 December 2021.
As an early Christmas gift to seniors struggling to pay for high drug costs, Congresswoman Carolyn Maloney, D-NY, released a 269-page majority staff report on Dec. 10 from the House Committee on Oversight and Reform, summarizing a three-year investigation of the pharmaceutical industry’s pricing and business practices.
Posted in Health, Finance & Work, Pushback0 Comments
The Senate Needs 50 Votes To Build A Better Medicare
Posted on 06 December 2021.
When elderly people were first created, they had no eyes, ears, and teeth. For this reason, when federal lawmakers got around to enacting Medicare insurance for seniors in 1965, they didn’t include vision services, hearing aids, and dental care.
Posted in Pushback0 Comments
Older Drivers Have A Difficult Time Giving Up The Keys
Posted on 01 November 2021.
The conventional wisdom is that older drivers are dangerous drivers. That canard has been shown to be untrue. But the issue of when older people should stop driving is one of the most contentious decision points in an older person’s life.
Posted in Family Care, Pushback0 Comments
Better Care Better Jobs Act Aims To Strengthen Human Infrastructure
Posted on 01 September 2021.
At the end of June, Congresswoman Debbie Dingell, D-MI and Senator Bob Casey, D-PA, introduced the “Better Care Better Jobs Act,”(S.2210) to widen access to Medicaid’s home and community based services for low-income elderly and disabled people, and to improve pay for the frontline caregivers who provide home care.
Posted in Health, Family Care, Pushback1 Comment
Aduhelm, New Alzheimer’s Drug, Tangled in Controversy
Posted on 20 July 2021.
Biogen estimates a target population of between 1 million to 1.2 million individuals could use this new drug. One Wall Street firm estimates that Biogen could reach Aduhelm sales of $5 billion by 2025.
Posted in Health, Pushback0 Comments